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NEW ANTIFUNGAL MEDICATION IMPACT ON MARKET SHARE AND
UTILIZATION OF TRADITIONAL AGENTS IN A SINGLE HEALTH
CARE SYSTEM
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1College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati, 
Cincinnati, OH, USA, 3The Health Alliance, Cincinnati, OH, USA
OBJECTIVES: The emergence of more resistant fungal pathogens necessitated devel-
opment of new antifungal agents. Three new antifungal medications (caspofungin, 
anidulafungin, voriconazole) entered the health care market from 2001–2006. The
objective of this study is to describe the impact of these new agents on drug utilization 
and charges in a single health care system. METHODS: Retrospective descriptive
analyses were conducted to describe trends in utilization of and charges associated
with antifungal medications in a 7-hospital health-system from 2005–2007. Data was
obtained from the hospital accounting/inventory management systems. The new anti-
fungal agents were compared to traditional ones (amphotericin B, ﬂ uconazole, itra-
conazole). The proportion of total charge and total doses of each antifungal were 
calculated as proxies of market share and utilization, respectively. Charge data were
converted to $2007 using the medical component of the CPI. RESULTS: Total doses 
dispensed were 51,845 to 12,471 patients. Utilization of new antifungal agents was 
29%, 22% and 29% of antifungal medications in 2005, 2006 and 2007. These newer
drugs, however, comprised 71%, 55% and 61% of total antifungal charges in these
years. Amphotericin B/liposomal amphotericin B increased utilization by 79% (2.5–
4.3%) and increased market share 200% (8–22%) despite a reduction in mean 
charge/dose ($632 in 2005 and $610 in 2007). Fluconazole IV use dropped from 18%
to 9% with corresponding reduction in percent total charges from 10% to 7% (mean 
charge/dose $111 in 2005, $98 in 2007). Oral ﬂ uconazole had the largest utilization 
of all antifungals (50–56%). Its market share remained fairly constant (10%, 12%,
9% 2005–2007) with decreased mean charge/dose from $37 to $18. Itraconazole, oral 
and IV, accounted for very little market share and utilization. CONCLUSIONS: Use
of cost containing strategies and formulary management in real world practice have
restricted growth of market share and utilization of new antifungal agents and encour-
aged use of traditional medications.
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DRUG UTILIZATION REVIEW OF ANTIMICROBIAL DRUGS IN AN
OUTPATIENT PRIVATE PEDIATRIC SETTING
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OBJECTIVES: This study was carried out to assess the drug utilization pattern 
in a private pediatric outpatient setting with special reference to use of antimicrobial
drugs using the WHO recommended prescription and complimentary indicators. 
METHODS: The data were collected prospectively from 301 prescriptions. Prescrip-
tions were analyzed for WHO recommended prescription and complimentary indica-
tors. The results were represented as average o SEM or percentage. RESULTS:
The male patients contributed 60% to the sample. The maximum number of 
patients were between one to ﬁ ve years. The average number of drugs per encounter 
was 2.80 o 0.06 (range 1–5). Only one prescription had an injection prescribed 
in it. Less than 1% drugs were prescribed by generic name. Compliance to WHO 
Model List of Essential Medicines and National List of Essential Medicines was to 
the tune of 7.7% and 10.2%, respectively. Twenty percent of total encounters had an
antimicrobial drug. None of the patients were prescribed with more than one antimi-
crobial drug. The average duration of prescribed antimicrobial drug was 4.07 o 0.15 
days. Respiratory tract infection was the most common disease followed by asthma
and acute gastroenterotitis. Oral administration was the most frequent method of 
administration (84.2%), followed by inhalers (7%). A majority of drugs prescribed
were in the form of syrup (57.3%). Average cost of drugs per prescription was
Rs.142.68 o 2.31. Only 10.8% and 0.16% of total cost was spent on antimicrobial
drugs and on an injection respectively. CONCLUSIONS: The average number of 
drugs per prescription was within acceptable limits. Further, low use of antimicrobial
drugs and injections reﬂ ect the rational use of drugs in this setting. These results have 
provided preliminary insight into prescribing practices in private outpatient pediatric
setting.
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HOSPITAL LENGTH OF STAY AND COSTS ASSOCIATED WITH
INAPPROPRIATE TREATMENT OF CANDIDEMIA IN THE ICU
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OBJECTIVES: Candida sp. are a growing cause of nosocomial blood stream infections
(CBSI). Representing over 1/10th of all BSIs and causing high mortality, CBSI are of 
particular concern in the ICU. Such modiﬁ able risk factors (MRF) as the failure to 
remove central venous catheter (CVC), delayed administration and inappropriate
dosage of antifungals confer elevated mortality risk. We hypothesized that these MRFs
are associated with increased hospital length of stay (HLOS) and costs among ICU 
patients with proven CBSI. METHODS: We conducted a single-center retrospective
cohort study between 2004 and 2006 enrolling consecutive hospitalized patients with
culture-conﬁ rmed CBSI within 14 days of hospital admission and  1 dose of antifun-
gal treatment. Appropriate therapy was deﬁ ned as timely administration (within 24 
hours of suspicion of CBSI) of an adequately dosed antifungal agent to which the 
isolated pathogen was sensitive in vitro. HLOS was primary and hospital costs were 
secondary outcomes. RESULTS: Of 90 ICU patients identiﬁ ed (mortality 23%), 78
(87%) had a CVC of which 14 (18%) were not removed. Antifungal treatment was
delayed 24 hours in 76 (85%), 48 hours in 44 (49%) and dosed inappropriately in 
21 (23%) patients. Unadjusted HLOS and costs increased with increasing delay in
treatment administration (no delay: 12.89.9 days, $32,748$22,292; 24 hours:
24.717.8 days, $62,481$42,814; 48 hours: 27.718.7 days, $70,74849279); inad-
equate dosing of ﬂ uconazole showed similar differences (26.617.9 vs. 21.717.1 
days, p  0.262; $68,106$52,053 vs. $54,736$37,831, p  0.199). Similar trends 
were observed in the cohort of ICU survivors only. CONCLUSIONS: Both delay in 
and inappropriate dosing of antifungal therapy are associated with increased hospital 
resource utilization among ICU patients with CBSI. If conﬁ rmed in further analyses 
and studies, these MRFs may provide attractive targets for interventions designed to 
improve both clinical and economic outcomes of CBSI in the ICU. Funded by a 
research grant from Astellas Pharma US Inc.
PIN53
HEALTH CARE UTILIZATION OF ANTIBIOTICS WITHIN THE SLOVAK 
REPUBLIC
Tesar T, Foltan V, Binder R
Comenius University, Bratislava, Slovak Republic
OBJECTIVES: The aim of this study was to collect comparable and reliable data on 
the antibiotic therapy in Slovakia during the period 1998 – 2007. Special interest 
was paid to the trend of antibiotic usages and the relationship between antibiotic use 
and resistance was also studied. METHODS: Data of wholesalers (following ATC/
DDD), who are legally obliged provide this information to the Slovak Institute for
Drug Control, was used for the analysis. RESULTS: The collected data showed a sig-
niﬁ cant increase in antibiotic consumption from 1998 to 2007 in terms of deﬁ ned 
daily doses per 1000 inhabitants per day (DID) – in 1998 (29.733), in 2003 (30.705)
and in 2007 (34.364). We can see a noticeable increase in consumption of macrolides
(DID); in 1998 (2.976), in 2003 (3.693) and in 2007 (6.144) and a moderate increase 
in ﬂ uoroquinolones consumption – in 1998 (1.009), in 2003 (1.602) and in 2007 
(2.339). A signiﬁ cant decrease in ﬁ rst-generation cephalosporins consumption – in 
1998 (1.052), in 2003 (0.662) and in 2007 (0.370), and a noticeable increase in
consumption of second-generation cephalosporins – in 1998 (1.200), in 2003 (1.658)
and in 2007 (3.261) and third-generation cephalosporins in 1998 (0.015), in 2003
(0.118) and in 2007 (0.606) can be seen from this analysis. The results show that 
consumption of combinations of penicillins including beta-lactamase has increased – in 
1998 (2.977), in 2003 (4.645) and in 2007 (5.778), but consumption of beta-
lactamase sensitive penicillins has decreased – in 1998 (4.171), in 2003 (3.409) and 
in 2007 (2.343) in term of DID. From this study, the stable antibiotics consumption 
in ﬁ nancial term – in 1998 (€49,141,000), in 2003 (€59,078,000) and in 2007
(€54,680,000) can be seen. CONCLUSIONS: Adherence to principles of antibiotic 
policy lead to fundamental short and long term ﬁ nancial savings within health care 
systems.
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INCREASING CHC TREATMENT RATE IN US IS A COST-SAVING
STRATEGY
Zhang H, Mehra M, Dibello J
Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA
OBJECTIVES: The low treatment rate in chronic hepatitis C (CHC) is partially due 
to suboptimal SVR achieved with the current pegylated-interferon/ribavirin (P/R) 
therapy. Here we applied a compartment model to assess the potential impacts of a 
higher CHC treatment rates in the US. METHODS: This mathematical model was 
expressed by partial differential equations across population compartments based on
injection-drug-use status, CHC status (infection, diagnosis, genotypes, treatment, and 
SVR), and disease-progression status. Model inputs were based on published sources. 
Model was calibrated from 2002–2006 and matched closely with CDC reports 
and other published literature. The model was applied to assess impacts of a higher 
CHC treatment rate from 2007–2040. Key assumptions included: only the current
P/R treatment is available during 2007–2040; P/R durations consistent with current 
treatment guidelines by genotypes and costs $28,000/48-week. All costs were 
converted into 2007 dollars using 3% discount rate. RESULTS: When P/R treatment 
rate increased from the current 6% to 30% across all patient groups between 
2007–2040, a total of 431,000 more patients could be treated, leading to 236,716
more patients being cured, and resulting in 111,802 fewer CHC incidences, 110,543
fewer ALD incidences, and 160,679 fewer deaths. Cost increases with higher treatment 
rate strategy come from more treatments ($12.4 billion) and managing more 
P/R treatment failure patients ($9.4 billion). Cost savings mainly come from having
fewer diagnosed but not treated CHC patients to manage (-$20.5 billion) and
having fewer patients with advanced liver disease (ALD) to manage (-$6.1 billion).
Overall direct medical cost savings are projected at $4.8 billion compared to the 
base scenario of 6% treatment rate. CONCLUSIONS: Increasing P/R treatment 
rate could result in more patients being cured earlier, preventing CHC and ALD inci-
dences and saving lives. Our model projects increasing treatment rates could be a cost 
saving strategy.
